|
Dec 27
|
Lilly Completes Acquisition of POINT Biopharma
|
|
Dec 4
|
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
|
|
Sep 18
|
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
|
|
Apr 24
|
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
|
Apr 24
|
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|